The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Small Increased Risk for CIN & Cervical CA with TNF Inhibitors

Small Increased Risk for CIN & Cervical CA with TNF Inhibitors

January 21, 2016 • By Laura Newman

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—Women with rheumatoid arthritis (RA) are at increased risk for cervical intraepithelial neoplasia (CIN), and those taking a tumor necrosis factor (TNF) inhibitor are at increased risk of cervical cancer, according to a study from Sweden.

You Might Also Like
  • TNF Inhibitors Do Not Seem to Boost Cancer-Recurrence Rates
  • Increased Risk of Serious Infections During Early Anti-TNF Treatment
  • Newer Biologics for RA on Par with TNF-Inhibitors for CV Risk

“Whether this (the increase in invasive cancers) was due to the TNF inhibitors, disease severity, or exposure to other drugs, is not clear,” first author Dr. Hjalmar Wadstrom told Reuters Health by email. “Compared to other settings, such as immune suppression in organ transplantation, the risks we observed are much lower.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Wadstrom and colleagues conducted a national registry-based study of women with RA treated in Sweden between 1999 and 2012, comparing the 9,629 women who started a first TNF inhibitor with 34,984 biologics-naive patients and 300,331 women in the general population.

The researchers also reviewed national cervical cancer screening using the Swedish Cancer Registry, which collects information on Pap tests, both opportunistic and preplanned.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In comparison with the general population, women with RA who were not taking disease-modifying biologics had more cancer screenings (hazard ratio 1.08) and a higher risk of cervical intraepithelial neoplasia (CIN) grade 1 (HR 1.53), and CIN 2-3 (HR 1.39), but not of invasive cervical cancer (HR 1.09).

Risk of invasive cancer doubled (HR 2.10) in women taking TNF inhibitors compared with biologics-naive patients. Women on TNF inhibitors had no significant increased risk of CIN grade 1 (HR 1.23) but did have increased risk of CIN grade 2-3 (HR 1.36).

Dr. Seoyoung C. Kim of Brigham and Women’s Hospital and Harvard Medical School in Boston pointed out that the statistically significant increase in relative risks doesn’t correspond to large absolute risks. In a telephone interview, she said, “I’d hate to see people over-interpret these findings. The absolute risk for cervical cancer is very low.”

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Although the study did not provide data on universal use of the human papillomavirus (HPV) vaccine, Dr. Kim pointed out, “With it, we can eradicate 80% to 90% of the high-risk cervical cancers. We can also continue monitoring patients with Pap tests.”

Concerning to Dr. Kim is that women likely to benefit from TNF inhibitors might think they could lower their relative risk for cervical cancer by not taking disease-modifying medications. “Relative risk can be deceiving when the absolute risk is very low,” she said.

“We agree that HPV vaccine, in addition to screening, is a good way of further decreasing the risk of cervical cancer, irrespective of RA and TNF inhibitors, though different countries use different primary prevention programs,” Dr. Wadstrom told Reuters Health. “We also agree that it would be unfortunate if women were discouraged from using (disease-modifying) treatment for fear of cervical cancer, especially since uncontrolled inflammatory activity or alternative options to control it might in themselves be risk factors for cervical cancer.”

Pages: 1 2 | Single Page

Filed Under: Conditions, DMARDs & Immunosuppressives, Drug Updates, Rheumatoid Arthritis Tagged With: Cancer, cervical cancer, Rheumatoid Arthritis (RA), TNF, TNF inhibitors, tumor necrosis factor, Women

You Might Also Like:
  • TNF Inhibitors Do Not Seem to Boost Cancer-Recurrence Rates
  • Increased Risk of Serious Infections During Early Anti-TNF Treatment
  • Newer Biologics for RA on Par with TNF-Inhibitors for CV Risk
  • More Evidence TNF Inhibitors Raise Risk of Peripheral Neuropathy

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)